How Is NAFLD Diagnosed?

If you've been told you might have fatty liver disease — or you're wondering whether you should get tested — understanding how NAFLD (now called MASLD) is actually diagnosed can feel confusing. There's no single test that gives you a definitive answer. Instead, diagnosing fatty liver involves a combination of blood tests, imaging, scoring systems, and sometimes liver biopsy — each telling you something different about what's happening inside your liver.

This guide walks you through every diagnostic test in plain language: what it measures, what it can and can't tell you, what the numbers mean, and how the tests fit together to form a complete picture of your liver health. Whether you're newly concerned about fatty liver or already diagnosed and trying to understand your results, this is your reference.

⚡ Understand Your Results Right Now

Already have test results? Use the Liver Enzyme Checker to understand your ALT and AST, the FibroScan Interpreter to decode your liver stiffness and CAP score, or upload everything to the report tracker for a comprehensive view.

What Exactly Is Being Diagnosed?

When doctors diagnose NAFLD/MASLD, they're actually answering three separate questions:

The diagnosis also requires ruling out other causes of liver disease — viral hepatitis, alcohol-related liver disease, autoimmune conditions, medications, and other metabolic diseases. And under the new MASLD criteria, at least one cardiometabolic risk factor must be present (obesity, type 2 diabetes, high blood pressure, dyslipidemia, or elevated waist circumference).

Step 1: Blood Tests — The Starting Point

Liver Enzymes (Liver Function Tests / LFTs)

For most people, the diagnosis journey begins when routine blood work reveals abnormal liver enzymes. The key values are:

• ALT (alanine aminotransferase): The most liver-specific enzyme. Elevated ALT suggests liver cell damage. Normal range is generally below 33–40 U/L for men and below 25–32 U/L for women (varies by lab).

• AST (aspartate aminotransferase): Also released when liver cells are damaged, but less specific to the liver (also found in heart, muscle, kidneys).

• GGT (gamma-glutamyl transferase): Elevated in many liver conditions, including fatty liver. Also elevated by alcohol use and certain medications.

• Alkaline phosphatase (ALP): Elevated primarily in bile duct conditions, but can be mildly elevated in NAFLD.

• Bilirubin, albumin, INR: These measure liver function rather than damage. Usually normal in early NAFLD but become abnormal as disease progresses toward cirrhosis.

Read our full breakdown in the Complete Guide to Liver Function Tests.

Critical caveat: Normal liver enzymes do NOT rule out NAFLD. This is one of the most important facts in fatty liver diagnosis. Up to 80% of people with NAFLD have normal ALT levels. You can have significant liver fat, active NASH, and even early fibrosis — all while your liver enzymes appear perfectly normal. ALT measures ongoing cell damage, not the amount of fat or scar tissue already present. This is why blood tests alone are insufficient for diagnosing or excluding NAFLD.

Use the Liver Enzyme Checker to understand your values and upload all blood work to the report tracker.

Metabolic Panel

Because NAFLD/MASLD is a metabolic disease, your doctor should also check fasting glucose and HbA1c (screening for diabetes/pre-diabetes), lipid panel (total cholesterol, LDL, HDL, triglycerides), fasting insulin (to assess insulin resistance), and blood pressure. These are part of the diagnostic criteria for MASLD, which requires at least one cardiometabolic risk factor, and they inform your overall treatment plan.

Tests to Rule Out Other Liver Diseases

Before diagnosing NAFLD, your doctor should exclude other causes of liver fat and elevated enzymes. This typically includes hepatitis B surface antigen and hepatitis C antibody (to rule out viral hepatitis), iron studies (ferritin, transferrin saturation — to rule out hemochromatosis), autoimmune markers (ANA, ASMA, anti-LKM — to rule out autoimmune hepatitis), ceruloplasmin (to rule out Wilson's disease in younger patients), and a careful medication and alcohol history.

Step 2: Imaging — Seeing the Fat

Abdominal Ultrasound

Ultrasound is often the first imaging test for suspected fatty liver because it's widely available, non-invasive, painless, radiation-free, and relatively inexpensive. On ultrasound, a fatty liver appears brighter (more echogenic) than the adjacent kidney — the classic "bright liver" finding.

Strengths: Good at detecting moderate-to-severe steatosis (>30% fat). Widely available in every hospital and most clinics.

Limitations: Cannot reliably detect mild steatosis (5–30% fat) — this means many people with early fatty liver will have a "normal" ultrasound. Cannot distinguish between simple steatosis and NASH (it can't see inflammation). Cannot measure fibrosis accurately. Operator-dependent — results vary based on the technician's skill. Less reliable in patients with obesity (the ultrasound beam is attenuated by body fat).

Ultrasound is a good screening tool but is not sufficient alone for a complete NAFLD assessment.

FibroScan (Vibration-Controlled Transient Elastography / VCTE)

The FibroScan has become the most important single test in modern NAFLD diagnosis because it measures two critical things simultaneously:

CAP Score (Controlled Attenuation Parameter): Measures liver fat. Expressed in dB/m (decibels per meter). The 2025 AASLD guidelines suggest a CAP of ≥275 dB/m to detect at least grade 1 hepatic steatosis. Higher values indicate more fat:

Liver Stiffness Measurement (LSM): Measures fibrosis/scarring. Expressed in kilopascals (kPa). This is the critical value for determining how advanced your disease is:

Strengths: Non-invasive, painless, takes about 10 minutes. Provides both fat AND fibrosis data in one visit. Highly reproducible for monitoring over time. Widely endorsed by AASLD, EASL, and all major guidelines.

Limitations: Results can be falsely elevated by recent food (fast 2+ hours), active liver inflammation, alcohol consumption, liver congestion (heart failure), or obesity (use XL probe). Cannot definitively diagnose NASH — it can detect fat and scarring but not the specific pattern of inflammation that defines NASH.

Use the FibroScan Interpreter to understand your numbers and log every result in the FibroScan Tracker.

MRI-Based Tests (Advanced Imaging)

Two MRI-based tests offer the highest accuracy for NAFLD assessment, but are more expensive and less widely available:

MRI-PDFF (Proton Density Fat Fraction): The most accurate non-invasive measurement of liver fat. Quantifies hepatic fat as a percentage. A PDFF ≥5% confirms steatosis. Used primarily in clinical trials and for monitoring treatment response.

MR Elastography (MRE): The most accurate non-invasive measurement of liver fibrosis. Creates a color-coded "stiffness map" of the entire liver. More reliable than FibroScan in patients with severe obesity. Excellent for detecting advanced fibrosis (F3–F4).

These tests are typically reserved for patients with inconclusive FibroScan results, those with very high BMI where FibroScan may be unreliable, clinical trial enrollment, and cases where precise monitoring of treatment response is needed.

Step 3: Fibrosis Risk Scores — The Quick Calculators

Fibrosis risk scores are simple calculations that use routine blood tests (you may already have them) to estimate your likelihood of having significant or advanced fibrosis. They're the first line of fibrosis screening recommended by all major guidelines:

FIB-4 Score (The Most Important One)

FIB-4 is the most widely validated fibrosis screening tool. It uses just four variables: your age, AST, ALT, and platelet count. Your doctor can calculate it from routine blood work.

FIB-4 is excellent at ruling out advanced fibrosis (high negative predictive value when below 1.3). However, it has an "indeterminate zone" where additional testing is needed, and it's less accurate in younger patients (under 35) and older patients (over 65).

Other Fibrosis Scores

• NAFLD Fibrosis Score (NFS): Uses age, BMI, diabetes status, AST/ALT ratio, platelet count, and albumin. Similar to FIB-4 in purpose — rule out advanced fibrosis. Has similar indeterminate-zone limitations.

• APRI (AST to Platelet Ratio Index): Simple ratio of AST to platelets. Less accurate than FIB-4 for NAFLD specifically, but widely used.

• ELF (Enhanced Liver Fibrosis) Test: A blood test measuring three direct fibrosis biomarkers (HA, PIIINP, TIMP-1). More accurate than FIB-4 for identifying advanced fibrosis, but requires a specialized lab test (not available everywhere). The AASLD endorses ELF as an alternative to FibroScan for secondary risk assessment.

Step 4: The Diagnostic Algorithm — How It All Fits Together

The current AASLD-recommended approach for diagnosing and risk-stratifying NAFLD/MASLD uses a sequential two-tier system:

Tier 1 — Primary risk assessment (in primary care):

• Identify patients at risk: those with metabolic risk factors (obesity, diabetes, high cholesterol, high blood pressure), abnormal liver enzymes, or incidental finding of fatty liver on imaging

• Rule out other liver diseases (hepatitis B/C, autoimmune, alcohol, etc.)

• Calculate FIB-4 score from routine blood tests

• FIB-4 below 1.3 → Low risk. Monitor in primary care. Repeat in 1–2 years.

• FIB-4 above 1.3 → Proceed to Tier 2

Tier 2 — Secondary risk assessment (primary care or specialist):

• Perform FibroScan (VCTE) or ELF test

• FibroScan LSM below 8 kPa (or ELF below 7.7) → Low risk. Follow in primary care.

• FibroScan LSM 8–12 kPa (or ELF 7.7–9.8) → Intermediate risk. Consider additional testing (MRE) or hepatology referral.

• FibroScan LSM above 12 kPa (or ELF above 9.8) → High risk. Refer to hepatologist. Likely F3–F4. Candidate for treatment (resmetirom or semaglutide if F2–F3). May need biopsy if clinical uncertainty exists.

This stepped approach means that most patients can be fully assessed without a liver biopsy — using only blood tests, a simple calculation, and a FibroScan.

Step 5: Liver Biopsy — The Gold Standard (Used Selectively)

Despite the advances in non-invasive testing, liver biopsy remains the definitive test for three things that no other test can do with certainty: confirming the specific diagnosis of NASH/MASH (it's the only test that can definitively identify the pattern of hepatocyte ballooning + lobular inflammation), precisely staging fibrosis (F0–F4 using METAVIR or other scoring systems), and distinguishing between different causes of liver disease when multiple conditions may overlap.

What Happens During a Liver Biopsy

A needle is inserted through the skin between the lower ribs (guided by ultrasound) to extract a tiny cylinder of liver tissue — approximately 1–3 cm long and 1–2 mm wide. The procedure takes about 15–20 minutes and is performed under local anesthesia (you're awake but the area is numbed). You'll typically be monitored for 2–4 hours afterward. Most patients experience some discomfort at the biopsy site, but serious complications are uncommon.

Limitations of Biopsy

Despite being the "gold standard," biopsy has significant limitations. It samples only about 1/50,000th of the liver, which means sampling error is possible — the small piece may not represent the entire organ. It's invasive and carries small risks including pain (experienced by 20–30% of patients), bleeding (~1 in 500 risk of significant bleeding), and very rarely infection or damage to nearby organs. It's not practical for monitoring disease over time (you can't repeat biopsies every 6 months). And there's inter-observer variability — different pathologists may score the same sample differently.

When Is Biopsy Recommended?

In modern practice, liver biopsy for NAFLD is recommended only when non-invasive tests give conflicting or indeterminate results, when there's suspicion of a second liver disease alongside NAFLD, when a definitive NASH diagnosis would change management (though the FDA no longer requires biopsy for prescribing resmetirom or semaglutide), or in clinical trials requiring histologic endpoints.

The New Diagnostic Criteria: NAFLD vs. MASLD

In 2023, the international hepatology community renamed NAFLD to MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease). The diagnostic criteria shifted from an exclusionary definition ("non-alcoholic" = rule everything else out) to an inclusionary, positive definition:

In practice, the two definitions overlap 99% — nearly everyone diagnosed with NAFLD also meets MASLD criteria. The name change doesn't change your treatment. Read more in our NAFLD vs NASH explainer.

Who Should Be Screened for NAFLD/MASLD?

The AASLD and EASL now recommend targeted screening (case-finding) in people with metabolic risk factors. You should ask your doctor about NAFLD screening if you have type 2 diabetes or pre-diabetes (strongest risk factor — approximately 60% have NAFLD), obesity (BMI ≥30) or overweight with central adiposity (belly fat), metabolic syndrome (3 or more of: high waist, high triglycerides, low HDL, high blood pressure, high fasting glucose), a family history of fatty liver disease or cirrhosis, unexplained elevated liver enzymes, or polycystic ovary syndrome (PCOS — associated with higher NAFLD rates).

Take the Liver Health Quiz for a quick risk assessment.

What Your Doctor Can — and Can't — Tell You Without a Biopsy

This table summarizes what non-invasive tests can confidently determine versus what still requires biopsy:

Tracking Your Diagnosis Over Time

NAFLD diagnosis isn't a one-time event — it's the beginning of an ongoing monitoring process. Your liver can improve or worsen depending on your lifestyle and treatment. Track everything in one place:

• Liver enzymes: Upload every blood test to the report tracker. Use trend tracking to see if ALT, AST, and GGT are improving.

• FibroScan: Log every result (CAP + LSM) in the FibroScan Tracker. Compare over months and years to see if fat and fibrosis are decreasing.

• Metabolic markers: Track fasting glucose, HbA1c, lipids, and weight alongside liver values.

• Clinical scores: If fibrosis is advancing, your MELD and Child-Pugh scores become relevant — both calculated automatically when you upload labs.

• Imaging: Log ultrasound, CT, and MRI dates and findings in imaging tracking.

📊 Build Your Complete Liver Health Record

Create your free LiverTracker account to upload all lab reports, log FibroScan results, track imaging dates, visualize trends, ask the AI health chat questions like "What does my FibroScan mean?", and share everything with your doctor.

Frequently Asked Questions

Can a regular blood test detect fatty liver?

A standard liver function test (ALT, AST) can raise suspicion — but it cannot diagnose fatty liver. Normal liver enzymes do NOT rule out NAFLD (up to 80% of NAFLD patients have normal ALT). Blood tests are a starting point, not a definitive answer. If your doctor suspects fatty liver, imaging (ultrasound or FibroScan) is needed to confirm fat in the liver.

What is the best test for diagnosing NAFLD?

No single test is "the best" — diagnosis requires a combination. However, if you could only do one test, a FibroScan provides the most information in a single visit: both fat (CAP score) and fibrosis (LSM) data in about 10 minutes. For the most precise fat measurement, MRI-PDFF is superior. For the most precise fibrosis measurement, MR elastography or liver biopsy leads. But for practical, widely available, cost-effective assessment — FibroScan is the clear winner.

Do I need a liver biopsy to be diagnosed with NAFLD?

No. In modern practice, most patients with NAFLD can be fully diagnosed and staged using non-invasive tests (blood tests + FibroScan or equivalent). Even for prescribing FDA-approved MASH medications (resmetirom and semaglutide), liver biopsy is NOT required. Biopsy is reserved for cases with diagnostic uncertainty or when multiple liver diseases may coexist.

What does a FIB-4 score of 1.5 mean?

A FIB-4 of 1.5 falls in the indeterminate zone (1.3–2.67), which means your risk of advanced fibrosis can't be clearly ruled out with blood tests alone. You should proceed to a FibroScan or ELF test for more precise fibrosis assessment. This is exactly how the two-tier diagnostic algorithm works — FIB-4 is the first filter, and FibroScan/ELF is the second.

Is ultrasound enough to diagnose fatty liver?

Ultrasound can confirm moderate-to-severe fatty liver, but it misses mild cases (it can't reliably detect fat below about 30% of the liver), cannot measure fibrosis accurately, and cannot identify NASH. If your ultrasound shows fatty liver, you should still get fibrosis assessed (with FIB-4 + FibroScan) because the amount of fat matters less than the amount of scarring for your long-term outcomes.

My liver enzymes have been normal for years — could I still have fatty liver?

Yes. This scenario is common and is one of the biggest gaps in NAFLD detection. If you have metabolic risk factors (obesity, diabetes, high cholesterol, high blood pressure), you should be screened for NAFLD regardless of your liver enzyme levels. Ask your doctor about a FIB-4 calculation and consider a FibroScan.

Medical References & Sources

1. EASL–EASD–EASO. Clinical Practice Guidelines on the management of MASLD. Journal of Hepatology. 2024. J Hepatol

2. AASLD. Clinical Assessment and Management of MASLD. AASLD Guidelines

3. AASLD. Spare Me the Jab: Noninvasive Assessment of Patients with MASLD. AASLD Clinical Pearls

4. NCBI StatPearls. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). August 2025. NCBI Bookshelf

5. American Liver Foundation. NASH Diagnosis: Testing Methods & Procedures. ALF

6. RadioGraphics. Current Update on Nomenclature, Diagnosis, and Management of MASLD: Radiologists' Perspective. 2025. RadioGraphics

Related Articles & Tools on LiverTracker

• NAFLD vs NASH: What's the Difference?

• What Is a FibroScan? How Non-Invasive Liver Testing Works

• Complete Guide to Liver Function Tests

• NAFLD/MASLD Condition Guide

• Cirrhosis Stages Explained

• Portal Hypertension and Varices

• What Is MELD Score?

• Child-Pugh Score Explained

• FibroScan Interpreter

• Liver Enzyme Checker

• Liver Health Quiz

• MELD Score Calculator

• Browse All Articles

🎯 Knowledge Empowers — Tracking Protects

Understanding how NAFLD is diagnosed is the first step. Tracking your results over time is how you stay ahead of the disease. Upload your labs, log your FibroScan, watch your trends, and share everything with your doctor.

→ Check Your Liver Enzymes

→ Interpret Your FibroScan

→ Create Your Free Account

→ Download the iOS App

Medical Disclaimer: This article is for informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Only your doctor can diagnose NAFLD/MASLD — this guide explains the process to help you understand and engage with your care. LiverTracker does not provide medical advice. For our complete disclaimer, visit livertracker.com/medical-disclaimer.